{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:46:09Z","timestamp":1794048369263,"version":"4.8.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":112,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Gold Coast Hospital and Health Service (GCHHS) and Gold Coast Hospital Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:italic>Neisseria gonorrhoeae<\/jats:italic>\n                    (NG) causes significant morbidity globally, and no licensed vaccine currently exists. Observational studies suggest the four-component meningococcal B (4CMenB) vaccine may provide cross-protection against NG. We conducted MenGO, an open-label, randomized controlled trial to evaluate the efficacy, safety, and immunogenicity of 4CMenB against NG in gay and bisexual men (GBM). Participants were randomized 1:1 to receive two doses of 4CMenB, or no vaccine, and were followed for 2 years with 3-monthly visits. 4CMenB vaccination did not significantly reduce gonorrhoea incidence (incidence rate ratio 0.78 (95% confidence interval (CI) 0.40-1.51;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.457), and no study-related serious adverse events occurred. The vaccine was immunogenic against NG, with higher serum bactericidal activity (hSBA) median titres at 6 months in vaccinated compared to unvaccinated participants (4 [interquartile range (IQR) 2-8] vs 2 [IQR 2-2];\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0021). However, hSBA titres did not increase in participants with an NG infection at the time of vaccination (2 [IQR 2-2] to 2 [IQR 2-4];\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090\u00b7999), whereas those without NG infection showed an increase from baseline to 6 months (2 [IQR 2-4] to 6 [IQR 2-16];\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0089). This study is limited by its small sample size based on an assumed vaccine efficacy of &gt;67% and was impacted by the COVID-19 pandemic. These findings provide important information for current 4CMenB vaccines programmes and gonorrhoea vaccine development and implementation.\n                  <\/jats:p>","DOI":"10.1038\/s41541-026-01422-y","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T14:49:09Z","timestamp":1776869349000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Efficacy of the meningococcal vaccine against Neisseria gonorrhoeae: a randomised clinical trial (MenGO)"],"prefix":"10.1038","volume":"11","author":[{"given":"Caroline","family":"Thng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharareh","family":"Eskandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengyi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew E.","family":"Grulich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maree","family":"O\u2019Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeny A.","family":"Semchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate L.","family":"Seib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"1422_CR1","unstructured":"WHO. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030. 2022. https:\/\/www.who.int\/publications\/i\/item\/9789240053779."},{"key":"1422_CR2","unstructured":"King J., Kwon J., McManus, H., Gray, R., & McGregor, S. HIV, viral hepatitis and sexually transmissible infections in Australia: Annual surveillance report 2024: The Kirby Institute, UNSW Sydney, Sydney, Australia, 2024."},{"key":"1422_CR3","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/S1473-3099(22)00175-X","volume":"22","author":"MW Traeger","year":"2022","unstructured":"Traeger, M. W. et al. Real-world trends in incidence of bacterial sexually transmissible infections among gay and bisexual men using HIV pre-exposure prophylaxis (PrEP) in Australia following nationwide PrEP implementation: an analysis of sentinel surveillance data. Lancet Infect. Dis. 22, 1231\u20131241 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"1422_CR4","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1258\/ijsa.2009.009235","volume":"21","author":"T Fowler","year":"2010","unstructured":"Fowler, T., Caley, M., Johal, R., Brown, R. & Ross, J. D. Previous history of gonococcal infection as a risk factor in patients presenting with gonorrhoea. Int J. STD AIDS 21, 277\u2013278 (2010).","journal-title":"Int J. STD AIDS"},{"key":"1422_CR5","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1071\/SH18097","volume":"16","author":"D Callander","year":"2019","unstructured":"Callander, D. et al. Gonorrhoea gone wild: rising incidence of gonorrhoea and associated risk factors among gay and bisexual men attending Australian sexual health clinics. Sex. Health 16, 457\u2013463 (2019).","journal-title":"Sex. Health"},{"key":"1422_CR6","first-page":"100364","volume":"16","author":"Y Li","year":"2022","unstructured":"Li, Y. et al. Estimated costs and quality-adjusted life-years lost due to N. gonorrhoeae infections acquired in 2015 in the United States: a modelling study of overall burden and disparities by age, race\/ethnicity, and other factors. Lancet Reg. Health Am. 16, 100364 (2022).","journal-title":"Lancet Reg. Health Am."},{"key":"1422_CR7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2174\/157016212800618138","volume":"10","author":"GA Jarvis","year":"2012","unstructured":"Jarvis, G. A. & Chang, T. L. Modulation of HIV transmission by Neisseria gonorrhoeae: molecular and immunological aspects. Curr. HIV Res. 10, 211\u2013217 (2012).","journal-title":"Curr. HIV Res."},{"key":"1422_CR8","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/0264-410X(91)90147-X","volume":"9","author":"JW Boslego","year":"1991","unstructured":"Boslego, J. W. et al. Efficacy trial of a parenteral gonococcal pilus vaccine in men. Vaccine 9, 154\u2013162 (1991).","journal-title":"Vaccine"},{"key":"1422_CR9","first-page":"29","volume":"65","author":"L Greenberg","year":"1974","unstructured":"Greenberg, L. et al. Gonococcal vaccine studies in Inuvik. Can. J. Public Health 65, 29\u201333 (1974).","journal-title":"Can. J. Public Health"},{"key":"1422_CR10","doi-asserted-by":"publisher","first-page":"106225","DOI":"10.1016\/j.jinf.2024.106225","volume":"89","author":"B Wang","year":"2024","unstructured":"Wang, B., Mohammed, H., Andraweera, P., McMillan, M. & Marshall, H. Vaccine effectiveness and impact of meningococcal vaccines against gonococcal infections: a systematic review and meta-analysis. J. Infect. 89, 106225 (2024).","journal-title":"J. Infect."},{"key":"1422_CR11","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S1473-3099(21)00812-4","volume":"22","author":"WE Abara","year":"2022","unstructured":"Abara, W. E. et al. Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study. Lancet Infect. Dis. 22, 1021\u20131029 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"1422_CR12","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/OLQ.0000000000001771","volume":"50","author":"AR Raccagni","year":"2023","unstructured":"Raccagni, A. R. et al. Meningococcus B vaccination effectiveness against Neisseria gonorrhoeae infection in people living with HIV: a case-control study. Sex. Transm. Dis. 50, 247\u2013251 (2023).","journal-title":"Sex. Transm. Dis."},{"key":"1422_CR13","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S1473-3099(21)00754-4","volume":"22","author":"B Wang","year":"2022","unstructured":"Wang, B. et al. Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study. Lancet Infect. Dis. 22, 1011\u20131020 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"1422_CR14","doi-asserted-by":"publisher","first-page":"e1341","DOI":"10.1093\/cid\/ciac436","volume":"76","author":"KJ Bruxvoort","year":"2023","unstructured":"Bruxvoort, K. J. et al. Prevention of Neisseria gonorrhoeae With Meningococcal B Vaccine: a matched cohort study in Southern California. Clin. Infect. Dis. 76, e1341\u2013e1349 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"1422_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae726","volume":"12","author":"B Wang","year":"2025","unstructured":"Wang, B. et al. Long-term 4CMenB vaccine effectiveness against gonococcal infection at four years post-program implementation: observational case-control study. Open Forum Infect. Dis. 12, ofae726 (2025).","journal-title":"Open Forum Infect. Dis."},{"key":"1422_CR16","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/S1473-3099(24)00236-6","volume":"24","author":"JM Molina","year":"2024","unstructured":"Molina, J. M. et al. Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 x 2 factorial design. Lancet Infect. Dis. 24, 1093\u20131104 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"1422_CR17","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1093\/cid\/ciy1061","volume":"69","author":"EA Semchenko","year":"2019","unstructured":"Semchenko, E. A., Tan, A., Borrow, R. & Seib, K. L. The Serogroup B Meningococcal Vaccine Bexsero Elicits Antibodies to Neisseria gonorrhoeae. Clin. Infect. Dis. 69, 1101\u20131111 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"1422_CR18","doi-asserted-by":"publisher","first-page":"e1008602","DOI":"10.1371\/journal.ppat.1008602","volume":"16","author":"I Leduc","year":"2020","unstructured":"Leduc, I. et al. The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae. PLoS Pathog. 16, e1008602 (2020).","journal-title":"PLoS Pathog."},{"key":"1422_CR19","doi-asserted-by":"publisher","first-page":"e625","DOI":"10.1016\/S1473-3099(25)00543-2","volume":"25","author":"F Martinon-Torres","year":"2025","unstructured":"Martinon-Torres, F. & Duran-Parrondo, C. Galicia\u2019s gonorrhoea vaccination programme. Lancet Infect. Dis. 25, e625 (2025).","journal-title":"Lancet Infect. Dis."},{"key":"1422_CR20","unstructured":"Agency UHS. Guidance: A guide to the Meningococcal B vaccine for protection against Gonorrhoea. Health Protection; 2025."},{"key":"1422_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-023-15516-y","volume":"23","author":"C Thng","year":"2023","unstructured":"Thng, C., Semchenko, E. A., Hughes, I., O\u2019Sullivan, M. & Seib, K. L. An open-label randomised controlled trial evaluating the efficacy of a meningococcal serogroup B (4CMenB) vaccine on Neisseria gonorrhoeae infection in gay and bisexual men: the MenGO study protocol. BMC Public Health 23, 607 (2023).","journal-title":"BMC Public Health"},{"key":"1422_CR22","unstructured":"BEXSERO - multi-component Meningococcal B vaccine (recombinant, adsorbed) suspension for injection 0.5 ml pre-filled syringe without needle (190718). Australian Register of Therapeutic Goods. 14 ed. Australia, 2013. https:\/\/www.tga.gov.au\/resources\/artg\/190718"},{"key":"1422_CR23","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. U.S Department of Health and Human Services; 2017."},{"key":"1422_CR24","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/978-1-0716-1900-1_19","volume":"2414","author":"EA Semchenko","year":"2022","unstructured":"Semchenko, E. A., Jen, F. E., Jennings, M. P. & Seib, K. L. Assessment of serum bactericidal and opsonophagocytic activity of antibodies to gonococcal vaccine targets. Methods Mol. Biol. 2414, 363\u2013372 (2022).","journal-title":"Methods Mol. Biol."},{"key":"1422_CR25","doi-asserted-by":"crossref","unstructured":"Gottlieb, S. L. et al. Gonococcal vaccines: Public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019. Vaccine 38, 4362\u20134373 (2020).","DOI":"10.1016\/j.vaccine.2020.02.073"},{"key":"1422_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/infdis\/jiae383","volume":"231","author":"WE Abara","year":"2025","unstructured":"Abara, W. E., Kirkcaldy, R. D., Bernstein, K. T., Galloway, E. & Learner, E. R. Effectiveness of MenB-4C vaccine against Gonorrhea: a systematic review and meta-analysis. J. Infect. Dis. 231, 61\u201370 (2025).","journal-title":"J. Infect. Dis."},{"key":"1422_CR27","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S1473-3099(21)00744-1","volume":"22","author":"LK Whittles","year":"2022","unstructured":"Whittles, L. K., Didelot, X. & White, P. J. Public health impact and cost-effectiveness of gonorrhoea vaccination: an integrated transmission-dynamic health-economic modelling analysis. Lancet Infect. Dis. 22, 1030\u20131041 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"1422_CR28","doi-asserted-by":"publisher","first-page":"e2331742","DOI":"10.1001\/jamanetworkopen.2023.31742","volume":"6","author":"SG Robison","year":"2023","unstructured":"Robison, S. G. & Leman, R. F. Association of group B Meningococcal vaccine receipt with reduced Gonorrhea incidence among university students. JAMA Netw. Open 6, e2331742 (2023).","journal-title":"JAMA Netw. Open"},{"key":"1422_CR29","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","volume":"23","author":"R Borrow","year":"2005","unstructured":"Borrow, R., Balmer, P. & Miller, E. Meningococcal surrogates of protection\u2014serum bactericidal antibody activity. Vaccine 23, 2222\u20132227 (2005).","journal-title":"Vaccine"},{"key":"1422_CR30","doi-asserted-by":"publisher","first-page":"e202","DOI":"10.1093\/cid\/ciaf372","volume":"81","author":"B Wang","year":"2025","unstructured":"Wang, B. et al. Long-term protection against invasive Meningococcal B disease and gonococcal infection 5 years after implementation of funded childhood and adolescent 4CMenB vaccination program in South Australia: an observational cohort and case-control study. Clin. Infect. Dis. 81, e202\u2013e210 (2025).","journal-title":"Clin. Infect. Dis."},{"key":"1422_CR31","doi-asserted-by":"publisher","first-page":"E715","DOI":"10.1503\/cmaj.130257","volume":"185","author":"MD Snape","year":"2013","unstructured":"Snape, M. D. et al. Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose. CMAJ 185, E715\u2013E724 (2013).","journal-title":"CMAJ"},{"key":"1422_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-01025-5","volume":"9","author":"L Argante","year":"2024","unstructured":"Argante, L., Prunas, O., Medini, D. & Ypma, E. Modeling the persistence of 4CMenB vaccine protection against real world meningococcal B disease in adolescents. NPJ Vaccines 9, 239 (2024).","journal-title":"NPJ Vaccines"},{"key":"1422_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1248613","volume":"14","author":"T Belcher","year":"2023","unstructured":"Belcher, T., Rollier, C. S., Dold, C., Ross, J. D. C. & MacLennan, C. A. Immune responses to Neisseria gonorrhoeae and implications for vaccine development. Front. Immunol. 14, 1248613 (2023).","journal-title":"Front. Immunol."},{"key":"1422_CR34","doi-asserted-by":"publisher","first-page":"e448","DOI":"10.1016\/S2352-3018(18)30072-9","volume":"5","author":"M Holt","year":"2018","unstructured":"Holt, M. et al. Community-level changes in condom use and uptake of HIV pre-exposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013\u201317. Lancet HIV 5, e448\u2013e456 (2018).","journal-title":"Lancet HIV"},{"key":"1422_CR35","doi-asserted-by":"publisher","first-page":"ofaa536","DOI":"10.1093\/ofid\/ofaa536","volume":"8","author":"EPF Chow","year":"2021","unstructured":"Chow, E. P. F., Hocking, J. S., Ong, J. J., Phillips, T. R. & Fairley, C. K. Sexually transmitted infection diagnoses and access to a sexual health service before and after the national lockdown for COVID-19 in Melbourne, Australia. Open Forum Infect. Dis. 8, ofaa536 (2021).","journal-title":"Open Forum Infect. Dis."},{"key":"1422_CR36","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/QAI.0000000000002462","volume":"85","author":"MA Hammoud","year":"2020","unstructured":"Hammoud, M. A. et al. Physical distancing due to COVID-19 disrupts sexual behaviors among gay and bisexual men in australia: implications for trends in HIV and other sexually transmissible infections. J. Acquir Immune Defic. Syndr. 85, 309\u2013315 (2020).","journal-title":"J. Acquir Immune Defic. Syndr."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01422-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01422-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01422-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T08:27:56Z","timestamp":1786523276000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01422-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1422"],"URL":"https:\/\/doi.org\/10.1038\/s41541-026-01422-y","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"4 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"162"}}